Tenon Medical (TNON) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Greetings and welcome to the Tenon Medical First Quarter twenty twenty five Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. Your hosts today are Steve Foster, President and Chief Executive Officer and Kevin Williamson, Chief Financial Officer. Mr. Foster and Mr. Williamson will present results of operations for the first quarter ended 03/31/2025 and provide a corporate update. A p ...

Financial Data and Key Metrics Changes - The company reported a revenue growth of 12% year over year, reaching $28.3 million in Q1 2025, driven by solid new sales and renewal activity [4][14] - Adjusted EBITDA grew 50% year over year to $4.5 million, highlighting operational leverage and a profitable growth strategy [4][15] - GAAP net loss was approximately $1.5 million, or a loss of $0.12 per share, compared to a net loss of $2.9 million in the prior year [18] Business Line Data and Key Metrics Changes - The renewal of two contracts with the New York City Police Department contributed approximately $3.5 million in catch-up revenue [4][15] - The company went live with four new cities and one expansion in Q1, with a robust international ShotSpotter pipeline [5] - Resource Router is currently deployed in over 20 agencies, more than double its installed base in less than 18 months [10] Market Data and Key Metrics Changes - The company expects accelerated traction with ShotSpotter internationally in the second half of 2025 and early 2026 [6] - The California Assembly Bill 2975 mandates hospitals to deploy weapon protection systems by 2027, creating a significant market opportunity [11][12] - The company anticipates annual recurring revenue (ARR) to increase from $95.6 million at the beginning of 2025 to approximately $110 million at the beginning of 2026 [20] Company Strategy and Development Direction - The company is focused on expanding its platform and data aggregation capabilities to position itself as a leader in public safety technology [3] - Investments are being made in AI capabilities, particularly for the Crime Tracer and SafePoint solutions [17][12] - The company is taking risk mitigation efforts to address potential headwinds related to municipal funding and budgets [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of their offerings and the differentiated value they bring to cities like Chicago [6] - The company remains vigilant about headwinds but believes it is well-positioned to drive revenue and ARR growth for 2025 [13] - Management reaffirmed full-year revenue guidance of $111 million to $113 million, while slightly reducing adjusted EBITDA guidance to 20% to 22% [19][20] Other Important Information - The company ended Q1 with $11.7 million in cash and cash equivalents, compared to $13.2 million at the end of Q4 2024 [19] - The company repurchased 33,493 shares at an average price of $15.04 for approximately $504,000 in Q1 2025 [19] Q&A Session Summary Question: How does the company manage the pipeline across its broader suite of tools? - Management indicated that each product solution has its own pipeline metrics, with a solid pipeline across the platform, particularly in Resource Router and Crime Tracer [22][23] Question: What early feedback has been received on the revamped SafePoint product? - Management noted success in the healthcare vertical, with proof of concept deployments underway in major healthcare chains [24][25] Question: Will there be meaningful bookings from Plate Ranger this year? - Management expects bookings to be in the $1 million range, with significant revenue increases anticipated next year [28][29] Question: What is the expected sales cycle for SafePoint given the 2027 requirement? - Management indicated that the opportunity for SafePoint is more of a 2026 opportunity, with traction being made in other markets [37][38] Question: How should revenue progression be viewed for Q2? - Management suggested a reduction in Q2 revenue, with expectations for growth in Q3 and Q4 as investments begin to pay off [48] Question: What is the annualized cost of SafePoint compared to traditional solutions? - Management stated that SafePoint charges about $20,000 per year per lane, offering a compelling solution compared to traditional methods [59][60] Question: What are the international opportunities and timing for expansion? - Management highlighted excitement about returning to Brazil and ongoing discussions for expansion in other Latin American countries [66][68]

Semler Scientific (SMLR) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to the Semler Scientific First Quarter twenty twenty five Financial Results Conference Call. All participants will be in a listen only mode. After today's prepared remarks, as time permits, management will take questions submitted prior to this call via email. Please note this event is being recorded. Before we begin, Seminole Scientific needs to remind you that certain comments made during this call ...

Seer (SEER) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the SEER First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please pr ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $2,810,000, representing a 121% increase year over year compared to $1,270,000 in Q1 2024 [5][21] - Gross margins normalized to 42.4%, compared to 37% in Q4 2024 and 43.6% in Q3 2024 [5][22] - EBITDA loss narrowed to negative $540,000 from negative $840,000 in the same period last year [6][23] - Net loss for Q1 2025 was $710,000, down from a net loss of $850,000 in Q1 2024 [23] Business Line Data and Key Metrics Changes - Contract manufacturing revenue increased by 58% year over year, driven by demand from existing customers and new partnerships [5] - Consumer branded products revenue surged by 189% year over year, significantly boosted by the addition of Silly George [5] - The company expects continued growth in both contract manufacturing and consumer products, with a robust pipeline for 2025 [8][11] Market Data and Key Metrics Changes - The company is seeing increased interest in U.S.-made gels due to potential tariff impacts, which may enhance competitiveness against imported products [19] - There is a growing market for hydrogel applications, particularly in laser hair removal, with significant interest from major companies [42] Company Strategy and Development Direction - The company plans to expand its product lines, including new offerings for MetaGel and Cancoderm, and is transitioning Silly George into a broader beauty brand [12][13] - The partnership with Stata is progressing well, with plans for additional product launches in 2025 and 2026 [14] - The company is strategically managing cash and R&D to ensure high ROI while pursuing growth opportunities [14] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about achieving $13,000,000 in revenue and cash flow positivity in 2025 despite external challenges [20] - The company is monitoring tariff situations closely and is prepared to adjust manufacturing strategies if necessary [16][19] - Management expressed confidence in the growth potential of their products and the overall market, despite uncertainties in the broader economic environment [60] Other Important Information - The company has a cash balance of approximately $1,190,000 as of March 31, 2025 [23] - The company has 7,654,537 shares of common stock outstanding as of May 13, 2025 [23] Q&A Session Summary Question: How much revenue was expected from AbbVie, and does the delay affect guidance? - Management indicated that not much revenue was baked in from AbbVie, so the delay should not significantly impact the $13,000,000 projection [25][26] Question: Can you provide details on the product launch with Stata? - The first product is Histosol, a digestive enzyme, with plans for additional digestive enzymes in the future [30] Question: Is there a seasonal improvement expected for Silly George? - Management expects seasonal growth, especially with new product launches planned for Q3 and Q4 [61][62] Question: Will transitioning manufacturing to Texas impact other business lines? - The company has built a new clean room with enough capacity to accommodate potential shifts in manufacturing [35][36] Question: Will the company survive on current cash reserves until EBITDA positive? - Management believes they can manage with current cash reserves until reaching EBITDA positivity [66]

NeuroPace (NPCE) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Greetings, and welcome to the NeuroPace First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce Jeremy Feffer of LifeSci Advisors. Please go ahead. Speaker1 Good afternoon. Thank you for joining us for Neuropace's first quarte ...

Lineage Cell Therapeutics (LCTX) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Welcome to the Lineage Cell Therapeutics First Quarter twenty twenty five Conference Call. At this time, all participants are in a listen only mode. An audio webcast of this call is available on the Investors section of Lineage's website at www.lineagecell.com. This call is subject to copyright and is the property of Lineage, and recordings, reproductions, or transmissions of this call without the express written consen ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 decreased by 5.8% to $4.2 million compared to $4.5 million in the same period last year [11] - SaaS revenue grew by 9.8% to $1.5 million, driven by early successes in payables automation [11] - Professional services revenue decreased by 13.2% to $2.2 million, accounting for 51% of total revenue compared to 55% last year [12] - Net loss for Q1 was $728,000, compared to a net loss of $175,000 for the same period last year [13] - Adjusted EBITDA for the quarter was $77,000, down from $673,000 in Q1 2024 [14] Business Line Data and Key Metrics Changes - SaaS revenue increased due to payables automation, while professional services revenue declined due to timing issues [11][12] - The gross margin percentage increased to 67.6%, driven by a better revenue mix and improved SaaS margins [12][13] Market Data and Key Metrics Changes - The company experienced a record-breaking week with over $2.4 million in new project contracts, indicating strong demand from state agencies and commercial clients [9] - Recent political events have created uncertainty, but management is optimistic about future demand for their products and services [10] Company Strategy and Development Direction - The company is focusing on transforming into a predominantly SaaS-driven business with a diverse suite of solutions [5] - Investments are being made in sales and marketing, as well as IT infrastructure, to enhance customer trust and cybersecurity [7] - The company plans to continue scaling its business and expects to see returns on these investments in late 2025 and beyond [7][16] Management's Comments on Operating Environment and Future Outlook - Management acknowledges headwinds in the building industry due to high interest rates and tariffs but remains optimistic about future growth [23] - The company expects to grow revenues year-over-year for fiscal 2025, particularly in SaaS revenues, while maintaining positive adjusted EBITDA [16] Other Important Information - The company has temporarily paused aggressive debt prepayments to focus on sales and marketing initiatives [15] - A shelf registration has been filed to strengthen the balance sheet and act quickly on market opportunities [15] Q&A Session Summary Question: How many implementations will you have and what would those mean in terms of annual recurring revenue? - The company will have about 22 to 23 customers using the SaaS product for payables automation [19] Question: How is the implementation of purchase orders progressing? - The first release of payables order was launched in April, with positive initial feedback [20][21] Question: Are there any customer hesitations regarding implementation timing? - Hesitation is more related to market conditions rather than the company's product [23] Question: Are the new orders in professional services stable in terms of margin opportunities? - Yes, the company has a strong backlog with over $3 million of work queued [27] Question: Does the company still serve over 600 K-12 customers? - Yes, the company has launched new products in the K-12 market and is seeing good growth [28][29]

Intellicheck (IDN) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Gar Jackson, Investor Relations. Thank you, sir. You may begin. Speaker1 Thank you, operator. Good afternoon, and thank you for joining us today for the Intellicheck first Quarter twenty twenty five Earnings Call. Before we get started, I will take a few minutes to read the forward looking statement. Certain statements in this conference c ...

Financial Data and Key Metrics Changes - Operating expenses decreased from $31.5 million in Q1 2024 to $25.1 million in Q1 2025, representing a 20% reduction [24] - Net loss for Q1 2025 was $19.7 million or $0.51 per share, compared to a net loss of $30.5 million or $1.31 per share in Q1 2024 [24] - Cash, cash equivalents, and short-term investments at the end of Q1 2025 were $68.4 million, down from $94.1 million at the end of 2024, with an estimated cash runway into Q1 2026 [24] Business Line Data and Key Metrics Changes - The primary focus remains on the submission of the Biologics License Application (BLA) for INO-3107, targeting recurrent respiratory papillomatosis (RRP) [5][6] - Significant progress was made in resolving manufacturing issues related to the Selectra device, with device design verification testing initiated [6][9] Market Data and Key Metrics Changes - RRP affects approximately 14,000 people in the US, with ongoing research suggesting this number may be an underestimate [15][30] - The current standard of care for RRP is surgery, which does not address the underlying disease, highlighting the urgent need for non-surgical treatment options [16] Company Strategy and Development Direction - The company aims to submit the BLA for INO-3107 by mid-2025, with a goal of receiving FDA acceptance by the end of the year [5][13] - The strategy includes leveraging market research insights to position INO-3107 as a preferred treatment option for patients and healthcare providers [7][18] - The company is also advancing its DNA encoded monoclonal antibody (dMAb) technology, which has shown promising interim results in clinical trials [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of INO-3107 to change the treatment paradigm for RRP, emphasizing the importance of each surgery to patients [73] - The company is focused on maintaining or improving clinical benefits seen to date and plans to submit a proposed protocol for a supplemental BLA in the future [14] Other Important Information - The company has been actively engaging with the RRP community and presenting data at scientific conferences to raise awareness of INO-3107 [10][11] - The dMAb technology is being explored for various disease targets, with initial proof of concept data showing durable antibody production [21][22] Q&A Session Summary Question: Details on the COSM presentation - The presentation will focus on surgery counts and additional data will be submitted for peer review [27][29] Question: Number of MSLs to onboard and epidemiology data - The company is conducting research to update the 14,000 active cases figure, which is believed to be an underestimate [30][31] Question: Expectation for surgery sparing claims and competitive differentiation - The FDA recognizes the clinical benefit of reduced surgeries, and the company believes it has a solid rationale for accelerated approval despite potential competition [36][46] Question: Plans for additional data in the filing package - The clinical package has been strengthened with detailed immunology characterization and durability data, and is ready for submission [48][49] Question: Pricing strategy and commercialization plans - Initial pricing is expected to be in line with other rare disease treatments, with plans to market INO-3107 in the US independently while considering partnerships for international markets [56][58] Question: Disclosure of baseline characteristics for the confirmatory trial - The patient population will be representative of the normal RRP population, with a focus on HPV serotypes [66][69]